New Triple-Drug cocktail aims to shrink metastatic breast tumors

NCT ID NCT05524584

Recruiting now Disease control Sponsor: University of California, Irvine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a combination of three drugs (anastrozole, fulvestrant, and abemaciclib) can shrink or control tumors in people with a common type of advanced breast cancer (hormone receptor positive, HER2-negative). About 20 participants whose cancer has spread or returned after prior treatment will receive the combination. The goal is to see how many patients respond and how long the benefit lasts.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm Her2-receptor negative breast cancer hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER HER2-NEGATIVE BREAST CANCER HORMONE-RECEPTOR-POSITIVE BREAST CANCER METASTATIC BREAST CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Locations

Chao Family Comprehensive Cancer Center, University of California, Irvine
RECRUITING

Orange, California, 92868, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••